vendredi 9 février 2018

Onco Actu du 9 février 2018

1.4 Biologie - Technos

Genomenon and Saphetor Announce Collaboration to Share Genomic Data [Xconomy]

2.11 Etiologie - Alimentation

California coffee may soon come with a cancer warning, but should consumers worry? [CBS]

3.1 Prévention - Tabac

Big tobacco’s offer: $1 billion for research. Should scientists take it? [Science]

3.8 Prévention - Alimentation

No, Asparagus Won't Give You Cancer [ACSH]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Statement from FDA Commissioner Scott Gottlieb, M.D., on groundbreaking approval and interagency approach to bring stable supply of critical medical imaging isotope to the U.S. [FDA]

UK's NICE Finalizing Updated Breast Cancer Test Guidance Following Stakeholder Comments [Genome Web]

4.2 Dép., diag. & prono. - Génome

Genomics meets blockchain: Harvard team featuring George Church launches peer-to-peer genome sequencing startup [EndPoints]

4.9 Dép., diag. & prono. - Sein

QIAGEN launches predictive therascreen PITX2 test in Europe to guide treatment in high-risk breast cancer [Qiagen]

5.10 Traitements - Essais

Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology [Amgen]

Many mutations in one clinical-trial basket [Nature]

5.12 Immunothérapies

Patient Specific HLA Class I Genotype Influences Response to Immune Checkpoint Inhibitors [ESMO]

5.12.2 Immunothérapies - CAR-T

Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study [FiercePharma]

Drugs Don’t Work If People Can’t Afford Them: The High Price Of Tisagenlecleucel [Health Affairs Blog]

Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000 [Forbes]

5.3.4 Traitements - AMM (FDA, EMA,...)

ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer [Janssen]

FDA Approves New Treatment for Certain Neuroendocrine Tumors [NCI]

FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer [FDA]

5.5 ASCO

2018 Symposium Highlights Notable Research Advances in Genitourinary Cancers [ASCO]

5.5.3 ASCO (prostate)

Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer [Mass. General Hospital]

ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer [Janssen]

'Two years' extra life' for men with worst prostate cancer offers hope for 10,000 patients [The Telegraph]

Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years [NY Times]

5.6 ESMO

Teleconsulting to Bring Specialised Expertise in Rare Cancers Across Europe [ESMO]

6. Lutte contre les cancers

ASCO panel: Precision medicine in practice can be challenging [Healio]

6.10 Politiques

Steve Brine MP: Government’s ambition is ‘best cancer outcomes in the world’ [Cancer Research UK]

6.4 Médico-éco

Waiting to Treat the Cancer [NY Times]